Patients with long-term survival in malignant gliomas after photodynamic therapy

Close metadata

OBJECTIVE

Analysis of long-lived patients from the group of patients with glioblastomas after using photodynamic therapy in the structure of their complex treatment in order to assess the influence of various factors on their life expectancy.

MATERIAL AND METHODS

In total, a single-center, retrospective categorical study analyzed the long-term results of treatment of 63 patients with glioblastoma in the structure of complex treatment including photodynamic therapy. Clinical factors (age, sex, number of cases, preoperative Karnofsky index, location and size of the tumor, radicality of the operation), histological (nuclear polymorphism, mitosis, vascular proliferation, necrosis), immunohistochemical (Ki-67, p53 index) molecular-genetic factors (expression of VEGF, MGMT, IDH, CD34), amount of radiation and chemotherapy were analyzed.

RESULTS

In the entire group of patients, there was a direct correlation of life expectancy with MGMT status, IDH status, the number of courses of chemotherapy, the age of the patient, and the severity of the first surgical intervention.

CONCLUSION

Clinical features such as age at diagnosis and extent of surgical resection and amount of chemotherapy have predictive value in assessing their effect on life expectancy. Mutations in IDH and MGMT promoter methylation were the most important molecular factors determining long-term patient survival.

Keywords:

photodynamic therapy

neurooncology

malignant gliomas

long-term survival

Authors:

Rynda A.Yu.

Polenov Russian Neurosurgery Institute — Branch of the Almazov National Medical Research Center

SPIN RSCI: 2435-2776
Scopus AuthorID: 57219021071
ResearcherID: P-2157-2019
ORCID: 0000-0002-3331-4175

Olyushin V.E.

Polenov Russian Neurosurgical Institute — a branch Almazov of the National Medical Research Center

ORCID: 0000-0002-9960-081X

Rostovtsev D.M.

Polenov Russian Neurosurgery Institute — Branch of the Almazov National Medical Research Center

SPIN RSCI: 6323-2140
ORCID: 0000-0002-8956-7921

Kukanov K.K.

Polenov Russian Neurosurgical Institute — a branch Almazov of the National Medical Research Center

ORCID: 0000-0002-1123-8271

Sklyar S.S.

Polenov Russian Neurosurgical Institute — a branch Almazov of the National Medical Research Center

ORCID: 0000-0002-3284-9688

Zabrodskaya Yu.M.

Prof. A.L. Polenov Russian Research Institute of Neurosurgery — Branch V.A. Almazov National Medical Research Center of the Ministry of Health of Russia

SPIN RSCI: 8571-3190
Scopus AuthorID: 52865171100
ResearcherID: N-8406-2016
ORCID: 0000-0001-6206-2133

Received:

28.07.2023

Accepted:

22.11.2023

List of references:

Lu D, Wang C, Liu X. Trends and patterns of incidence of diffuse glioma in adults in the United States, 1973—2014. Cancer Medicine. 2018;7(10):5281-5290. https://doi.org/10.1002/cam4.1757
Ostrom QT, Cioffi G, Waite K, et al. CBTRUS Statistical Report: primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014—2018 Neuro. Oncol. 2021;23(12 suppl 2):iii1-iii105. https://doi.org/10.1093/NEUONC/NOAB200
Bonet LGG, Piqueras-Sánchez C, Roselló-Sastre E, et al. Long-term survival of glioblastoma: A systematic analysis of literature about a case. Neurocirugía. 2022;33(5):227-236. https://doi.org/10.1016/j.neucie.2021.11.001
Poon MTC, Sudlow CLM, Figueroa JD, et al. Longer-term (≥ 2 years) survival in patients with glioblastoma in population-based studies pre- and post-2005: a systematic review and meta-analysis. Sci Rep. 2020;10(1):11622. https://doi.org/10.1038/s41598-020-68011-4
Park CK, Bae JM, Park SH. Long-term survivors of glioblastoma are a unique group of patients lacking universal characteristic features. Neuro-Oncology Advances. 2020;2(1):vdz056. https://doi.org/10.1093/noajnl/vdz056
Matsko MV, Matsko DE, Volkov NM, et al. Morphologic and molecular features of primary glioblastoma in patients surviving more than 3 years. Siberian Journal of Oncology. 2019;18(3):34-44. (In Russ.). https://doi.org/10.21294/1814-4861-2019-18-3-34-44
Jiang H, Yu K, Cui Y, et al. Differential Predictors and Clinical Implications Associated with Long-Term Survivors in IDH Wildtype and Mutant Glioblastoma. Front. Oncol. 2021;11:632663. https://doi.org/10.3389/fonc.2021.632663
Alexopoulos G, Zhang J, Karampelas I, et al. Long-Term Time Series Forecasting and Updates on Survival Analysis of Glioblastoma Multiforme: A 1975—2018 Population-Based Study. Neuroepidemiology. 2022;56(2):75-89. https://doi.org/10.1159/000522611
Marton E, Giordan E, Siddi F, et al. Over ten years overall survival in glioblastoma: a different disease? J Neurol Sci. 2020;408:116518. https://doi.org/10.1016/j.jns.2019.116518
Zreik J, Moinuddin FM, Yolcu YU, et al. Improved 3-year survival rates for glioblastoma multiforme are associated with trends in treatment: analysis of the national cancer database from 2004 to 2013. J Neurooncol. 2020;148(1):69-79. https://doi.org/10.1007/s11060-020-03469-w
Goriaĭnov SA, Gol’dberg MF, Golanov AV, et al. The phenomenon of long-term survival in glioblastoma patients. Part I: the role of clinical and demographic factors and an IDH1 mutation (R 132 H). Zhurnal Voprosy Neirokhirurgii im. N.N. Burdenko. 2017;81(3):5-16. (In Russ.). https://doi.org/10.17116/neiro20178135-16
Reuss DE, Sahm F, Schrimpf D, et al. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an «integrated» diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. Acta Neuropathol. 2015;129(1):133-146. https://doi.org/10.1007/s00401-014-1370-3
Rynda A, Olyushin V, Rostovtsev D, et al. Long-term survival following photodynamic therapy for malignant glioma depending on MGMT status. Annals of Oncology. 2020;31(suppl 4):S402. https://doi.org/10.1016/j.annonc.2020.08.486
Michaelsen SR, Urup T, Olsen LR, et al. Molecular profiling of short-term and long-term surviving patients identifies CD34 mRNA level as prognostic for glioblastoma survival. J Neurooncol. 2018;137(3):533-542. https://doi.org/10.1007/s11060-017-2739-7
Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803-820.
Verhaak RGW, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17(1):98-110. https://doi.org/10.1016/j.ccr.2009.12.020
Cantero D, Mollejo M, Sepúlveda JM. TP53, ATRX alterations, and low tumor mutation load feature IDH-wildtype giant cell glioblastoma despite exceptional ultra-mutated tumors. Neurooncol Adv. 2020;2(1):vdz059. https://doi.org/10.1093/noajnl/vdz059
Chaurasia A, Park SH, Seo JW. Et al. Immunohistochemical Analysis of ATRX, IDH1 and p53 in Glioblastoma and Their Correlations with Patient Survival. J Korean Med Sci. 2016;31(8):1208-1214. https://doi.org/10.3346/jkms.2016.31.8.1208
Kong X, Guan J, Ma W, et al. CD34 Over-Expression is Associated with Gliomas’ Higher WHO Grade. Medicine (Baltimore). 2016;95(7):e2830. https://doi.org/10.1097/MD.0000000000002830
Li F, Li Y, Zhang K. FBLN4 as candidate gene associated with long-term and short-term survival with primary glioblastoma. Onco Targets Ther. 2017;10:387-395. https://doi.org/10.2147/OTT.S117165
Hermansen SK, Sorensen MD, Hansen A, et al. A 4-miRNA signature to predict survival in glioblastomas. PLoS One. 2017;12(11):e0188090. https://doi.org/10.1371/journal.pone.0188090
Rynda AYu, Olyushin VE, Rostovtsev DM, et al. Intraoperative fluorescence control with chlorin E6 in resection of glial brain tumors. Zhurnal Voprosy Neirokhirurgii im. N.N. Burdenko. 2021;85(4):20-28. (In Russ.). https://doi.org/10.17116/neiro20218504120
Hirschberg H, Berg K, Peng Q. Photodynamic therapy mediated immune therapy of brain tumors. Neuroimmunology and Neuroinflammation. 2018;5(27):1-16. https://doi.org/10.20517/2347-8659.2018.31
Rynda AYu, Olyushin VE, Rostovtsev DM, et al. Intraoperative photodynamic therapy in complex treatment of malignant gliomas. Burdenko’s Journal of Neurosurgery = Zhurnal voprosy neirokhirurgii im. N.N. Burdenko. 2023;87(1):25-34. (In Russ.). https://doi.org/10.17116/neiro20238701125
Shimizu K, Nitta M, Komori T, et al. Intraoperative Photodynamic Diagnosis Using Talaporfin Sodium Simultaneously Applied for Photodynamic Therapy against Malignant Glioma: A Prospective Clinical Study. Frontiers in Neurology. 2018;9:24. https://doi.org/10.3389/fneur.2018.00024
Rynda AYu, Rostovtsev DM, Olyushin VE, et al. Therapeutic pathomorphosis in malignant glioma tissues after photodynamic therapy with chlorin e6 (reports of two clinical cases). Biomedical Photonics. 2020;9(2):45-54. (In Russ.). https://doi.org/10.24931/2413-9432-2020-9-2-45-54
Scoccianti S, Magrini SM, Ricardi U, et al. Pat-terns of care and survival in a retrospective analysis of 1059 patients with glioblastoma multiforme treated between 2002 and 2007: a multicenter study by the Central Nervous System Study Group of Airo (Italian Association of Radiation Oncology). Neurosurgery. 2010;67(2):446-458. https://doi.org/10.1227/01.NEU.0000371990.86656.E8
Reifenberger G, Weber RG, Riehmer V, et al. Molecular characterization of long-term survivors of glioblastoma using genome- and transcriptome-wide profiling. Int J Cancer. 2014;135(8):1822-1831. https://doi.org/10.1002/ijc.28836
Gately L, McLachlan SA, Philip J, et al. Long-term survivors of glioblastoma: a closer look. J Neurooncol. 2018;136(1):155-162. https://doi.org/10.1007/s11060-017-2635-1
Tian M, Ma W, Chen Y, et al. Impact of gender on the survival of patients with glioblastoma. Biosci Rep. 2018;38(6):BSR20180752. https://doi.org/10.1042/BSR20180752
Tykocki T, Eltayeb M. Ten-year survival in glioblastoma. A systematic review. J Clin Neurosci. 2018;54:7-13. https://doi.org/10.1016/j.jocn.2018.05.002
Nitta M, Muragaki Y, Maruyama T, et al. Role of photodynamic therapy using talaporfin sodium and a semiconductor laser in patients with newly diagnosed glioblastoma. Journal of Neurosurgery. 2018;131(5):1-8. https://doi.org/10.3171/2018.7.JNS18422
Akimoto J, Haraoka J, Aizawa K. Preliminary clinical report on safety and efficacy of photodynamic therapy using talaporfin sodium for malignant gliomas. Photodiagnosis and Photodynamic Therapy. 2012;9(2):91-99. https://doi.org/10.1016/j.pdpdt.2012.01.001
Hartmann C, Hentschel B, Simon M. Long-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations. Clin Cancer Res. 2013;19(18):5146-5157. https://doi.org/10.1158/1078-0432.CCR-13-0017
Gerber NK, Goenka A, Turcan S. Transcriptional diversity of long-term glioblastoma survivors. Neuro Oncol. 2014;16(9):1186-1195. https://doi.org/10.1093/neuonc/nou043
Yuan GQ, Wei NL, Mu LY, et al. A 4-miRNAs signature predicts survival in glioblastoma multiforme patients. Cancer Biomark. 2017;20(4):443-452.
Rynda A, Olyushin V, Rostovtsev D, et al. Influence of the expression of ABCG2 transporters on the results of photodynamic therapy in malignant gliomas. Annals of Oncology. 2021;32(suppl 5):S523. https://doi.org/10.1016/j.annonc.2021.08.026
Emery IF, Gopalan A, Wood S, et al. Expression and function of ABCG2 and XIAP in glioblastomas. J Neurooncol. 2017;133(1):47-57. https://doi.org/10.1007/s11060-017-2422-z

Close metadata